GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Leap Therapeutics Inc (NAS:LPTX) » Definitions » PB Ratio

Leap Therapeutics (Leap Therapeutics) PB Ratio : 1.17 (As of May. 14, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Leap Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-14), Leap Therapeutics's share price is $2.75. Leap Therapeutics's Book Value per Share for the quarter that ended in Dec. 2023 was $2.35. Hence, Leap Therapeutics's PB Ratio of today is 1.17.

The historical rank and industry rank for Leap Therapeutics's PB Ratio or its related term are showing as below:

LPTX' s PB Ratio Range Over the Past 10 Years
Min: 0.19   Med: 1.42   Max: 7.13
Current: 1.2

During the past 12 years, Leap Therapeutics's highest PB Ratio was 7.13. The lowest was 0.19. And the median was 1.42.

LPTX's PB Ratio is ranked better than
75.38% of 1312 companies
in the Biotechnology industry
Industry Median: 2.48 vs LPTX: 1.20

During the past 12 months, Leap Therapeutics's average Book Value Per Share Growth Rate was -60.40% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -33.00% per year.

During the past 12 years, the highest 3-Year average Book Value Per Share Growth Rate of Leap Therapeutics was 81.10% per year. The lowest was -33.00% per year. And the median was -4.60% per year.

Back to Basics: PB Ratio


Leap Therapeutics PB Ratio Historical Data

The historical data trend for Leap Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Leap Therapeutics PB Ratio Chart

Leap Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 2.88 2.65 0.76 1.76

Leap Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.76 1.43 0.95 0.49 1.76

Competitive Comparison of Leap Therapeutics's PB Ratio

For the Biotechnology subindustry, Leap Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Leap Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Leap Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Leap Therapeutics's PB Ratio falls into.



Leap Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Leap Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=2.75/2.352
=1.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Leap Therapeutics  (NAS:LPTX) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Leap Therapeutics PB Ratio Related Terms

Thank you for viewing the detailed overview of Leap Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Leap Therapeutics (Leap Therapeutics) Business Description

Traded in Other Exchanges
Address
47 Thorndike Street, Suite B1-1, Cambridge, MA, USA, 02141
Leap Therapeutics Inc is a biopharmaceutical company developing novel therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways and by harnessing the immune system to attack cancer cells. Its clinical stage program is DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1. DKK1 is a protein that regulates the Wnt signaling pathways and enables tumor cells to proliferate and spread, as well as suppresses the immune system from attacking the tumor. The company is studying DKN-01 in multiple ongoing clinical trials in patients with esophagogastric cancer, gynecologic cancers, or prostate cancer. Its other clinical studies include P204,and P205.
Executives
Jason Baum officer: Chief Scientific Officer LEAP THERAPEUTICS, INC., 47 THORNDIKE STREET, SUITE B1, CAMBRIDGE MA 02141
Patricia A. Martin director 316 BEECHWOOD FARM LANE, INDIANAPOLIS IN 46260
Christian M Richard director 100 FEDERAL STREET, 19TH FLOOR, BOSTON MA 02110
Richard Schilsky director LEAP THERAPEUTICS, INC., 47 THORNDIKE STREET, SUITE B1, CAMBRIDGE MA 02141
Beigene, Ltd. 10 percent owner C/O MOURANT GOVERNANCE SERVICES (CAYMAN), 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108
Christine Granfield officer: VP, Head of Reg Affairs/Qual C/O LEAP THERAPEUTICS, 47 THORNDIKE STREET, SUITE B1-1, CAMBRIDGE MA 02141
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
John Mark O'mahony officer: Chief Manufacturing Officer C/O LEAP THERAPEUTICS, INC., 47 THORNDIKE STREET, SUITE B1-1, CAMBRIDGE MA 02141
Cynthia Sirard officer: Chief Medical Officer C/O LEAP THERAPEUTICS, INC., 47 THORNDIKE STREET, SUITE B1-1, CAMBRIDGE MA 02141
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Christopher Mirabelli director, 10 percent owner, officer: CEO,Pres,Chairman of the Board 55 CAMBRIDGE PARKWAY, SUITE 301, CAMBRIDGE MA 02142
Augustine Lawlor 10 percent owner, officer: Chief Operating Officer 55 CAMBRIDGE PARKWAY, SUITE 301, CAMBRIDGE MA 02142
Douglas E Onsi 10 percent owner, officer: CFO,Gen Counsel,Treas, Sec. C/O TOLERRX INC, 300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Healthcare Ventures Ix, L.p. 10 percent owner 55 CAMBRIDGE PARKWAY, SUITE 102, CAMBRIDGE MA 02142

Leap Therapeutics (Leap Therapeutics) Headlines

From GuruFocus

Leap Therapeutics to Host Virtual R&D Day on July 12, 2022

By PRNewswire PRNewswire 06-27-2022